The next-generation sequencing assay is intended for use in identifying patients with ROS1, NTRK1-3, and ALK gene fusions in advanced solid tumors.
According to PathGroup, the deal will broaden its testing menu and adds more than 120 pathologists covering all pathology sub-specialties to the company.
The government payor asked the public to specifically weigh in on the evidence supporting germline testing to assess treatment benefit for patients with hereditary cancer syndromes.
The firm recently submitted an application to the US Food and Drug Administration to expand Cologuard's label to the 45 to 49 age group.
The company plans to present early data this year from its collaboration with Johnson & Johnson to develop a nasal swab-based lung cancer genomic classifier.
The firm will use the proceeds to further a validation study tracking the ability of its cell culture assay to predict patient response to cancer therapies.
The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.
The four-protein signature is associated with early forms of colon cancer that are most likely to progress into later stages of the disease.
The firm reported double-digit organic growth in North America, Europe, and China, driven in part by sales from its antibody portfolio and Simple Western instruments.
The companies were involved in a dispute over NeoGenomics' handling of Health Discovery technology it licensed in 2012 to develop cancer tests.
Investigators from a variety of clinical sites found that the company's liquid biopsy test was more successful in finding actionable mutations in patients than tumor tissue.
The cancer diagnostics developer said it was undertaking the reverse stock split in order to meet the Nasdaq's $1 minimum bid price requirement.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The approach makes use of a microfluidic probe that allows researchers to more effectively collect data on the kinetics of antibody-target reactions.
Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.
For the three months ended March 31, the molecular diagnostics company's revenues fell to $4.7 million from $9.7 million in Q1 2018.
The kit allows stable preservation and transport of blood samples for testing using the company's in-house clinical and research assays.
Idylla molecular testing instruments will be placed at Covance sites to support customer needs for clinical trials and to validate and implement companion diagnostic applications.
With the approval of its ThyraMIR diagnostic assay, the firm said that physicians will have access to its thyroid product suite across several specimen types.
LabCorp will further invest in OmniSeq as part of the deal, which covers distribution of the latter's immune profiling and pan-cancer next-generation sequencing tests.